New Codes for COVID Booster Vaccine & Monoclonal Antibody Products

August 10th, 2021 - Wyn Staheli, Director of Research
0 Votes - Sign in to vote or comment.

As part of ongoing efforts to treat and prevent COVID-19, new vaccines and therapies continue to be added which require new codes for reporting. The following are some changes that have happened recently.

COVID Booster Vaccine Code

On July 30, 2021, the American Medical Association (AMA) announced the addition of a new CPT code (0003A) to report the administration of a third dose of the Pfizer-BioNTech COVID-19 vaccine. Although the FDA granted approval for the first two doses of this vaccine back in December of 2020, according to the AMA website, the code for reporting the third booster dose is effective upon receiving Emergency Use Authorization (EUA) or approval from the FDA. The AMA updated their Appendix Q to reflect this new code.

Monoclonal Antibody Product

Prior to this new booster code, on June 24, 2021, CMS announced new codes (Q0249, M0249, M0250) to report the use of Genentech’s Antibody Tocilizumab for the treatment of COVID-19. Unlike other monoclonal antibodies, which are only authorized to treat a patient with mild-to-moderate COVID-19 who has NOT been hospitalized, Tocilizumab’s EUA is for patients 2 years of age and older who are already hospitalized with severe COVID-19 illness.

Novavax Vaccine Code 

On May 4, 2021, the AMA released new codes to report the Novavax two-dose vaccine; code (91304) and its associated administration codes (0041A, 0042A). These codes will be effective upon receiving emergency use authorization from the FDA. However, Novavax recently stated that they won’t be submitting that request until the fourth quarter of this year even though they plan on requesting an emergency use listing from the World Health Organization (WHO) sometime in August.


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

Delving Into the 360 Assessment Fraud Complaint
November 17th, 2021 - Jessica Hocker, CPC, CPB
The Department of Justice is pursuing claims of healthcare fraud against Cigna Health-Spring Medicare Advantage plan based on how they used data from their 360 Program in 2012. A review of the allegations may help other payers avoid similar accusations.
Lessons Learned from a RADV Audit Report
November 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
If given an opportunity to know ahead of time the questions that would be asked of you in an upcoming interview or quiz, it is likely the outcome would be significantly better than if you were surprised by the questions. This same concept may be applied to audits of risk ...
Changes in RPM for 2021! Now, Wait for it... New RTM Codes for 2022
November 11th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Remote physiologic monitoring and clinical data monitoring is a relatively new concept thriving and growing as an essential component for telehealth services. According to global consumer trends, a company called Dynata reported, "Among the 39% of people who consulted a healthcare professional, two-thirds used telemedicine, many of them for the first time ...
Reporting and Auditing Drug Testing Services
November 9th, 2021 - Aimee Wilcox CPMA, CCS-P, CST, MA, MT
Drug testing is a common medical service used to manage prescription medications, verify someone is not taking illegal substances or too much of a prescribed substance, and monitor for toxicity and therapeutic dosing. It is customary for patients in treatment programs for chronic pain management or substance use disorders (SUD) to undergo random urine drug testing (UDT) or urine drug screening (UDS) as part of their individual treatment plan. Drug testing is regulated by federal and state laws (e.g., OSHA, CLIA), which must be carefully adhered to.
Understanding ASCs and APCs: Indicators and Place of Service
October 28th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
The decision regarding the most appropriate care setting for a given surgical procedure is determined by the physician based on the patient's individual clinical needs and preferences. Of course, there is a difference in reimbursement, and the billing depends on where the procedure took place, such as an office setting, inpatient ...
Are You Keeping up with the Official ICD-10-CM Guideline Changes for COVID-19?
October 25th, 2021 - Wyn Staheli, Director of Research
The COVID-19 public health emergency (PHE) has made it interesting and challenging for organizations to keep an eye on the evolving changes to the ICD-10-CM Official Guidelines for Coding and Reporting. Have you been keeping up with these changes?
Is Your Organization Ready to Deal with Provider Relief Fund (PRF) Audit Contractors?
October 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Audits are currently underway to verify the monies distributed through the CARES Act were warranted and properly used by those organizations that received them. The federal government has contracted with financial institutions such as KPMG and PricewaterhouseCoopers, among others, to perform these audits referred to as Provider Relief Fund (PRF) audit contractors, funded with monies from the very same program. There were four phases of funding disbursements with phase 1 audits beginning in September. How ready are you to be audited?

Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association